Author: Falzarano, Darryl; de Wit, Emmie; Martellaro, Cynthia; Callison, Julie; Munster, Vincent J.; Feldmann, Heinz
Title: Inhibition of novel ß coronavirus replication by a combination of interferon-a2b and ribavirin Document date: 2013_4_18
ID: tgngoea8_12
Snippet: Here we identified a potential therapeutic approach against hCoV-EMC/2012 combining IFN-a2b and ribavirin. Either treatment alone reduced virus replication by at least 1-log or as much as 4-logs in susceptible cell lines. Moreover, when combined, efficacy was reached at lower concentrations. Thus, this combination may provide a benefit as a treatment in humans. Vero cells display a high level of resistance to the activity of ribavirin 19, 27 . Th.....
Document: Here we identified a potential therapeutic approach against hCoV-EMC/2012 combining IFN-a2b and ribavirin. Either treatment alone reduced virus replication by at least 1-log or as much as 4-logs in susceptible cell lines. Moreover, when combined, efficacy was reached at lower concentrations. Thus, this combination may provide a benefit as a treatment in humans. Vero cells display a high level of resistance to the activity of ribavirin 19, 27 . Thus, we also performed the same assay in LLC-MK2 cells, where sensitivity to ribavirin was observed at a much lower concentration.
Search related documents:
Co phrase search for related documents- benefit provide and combination benefit provide: 1, 2, 3
- benefit provide and high level: 1
- benefit provide and human treatment: 1
- benefit provide and therapeutic approach: 1
- benefit provide and virus replication: 1, 2, 3, 4
- cell line and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
- cell line and human treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- cell line and low concentration: 1, 2, 3, 4, 5, 6, 7, 8
- cell line and resistance high level: 1, 2
- cell line and ribavirin sensitivity: 1
- cell line and susceptible cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- cell line and therapeutic approach: 1, 2, 3, 4, 5, 6, 7, 8
- cell line and vero cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- cell line and virus replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- high level and human treatment: 1, 2, 3, 4, 5, 6
- high level and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9
- high level and resistance high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- high level and susceptible cell line: 1
- high level and therapeutic approach: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date